(Q28203270)

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Chromosome and molecular abnormalities in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Point mutations in the FLT3 gene in AML.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

The expression of FMS, KIT and FLT3 in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6926%2803%2900063-X

7 January 2021